- News>
- Companies & Commodities
Ranbaxy gets FDA nod for loratadine tablets
Mumbai, Aug 20: Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to market a generic version of Schering-Plough Corp`s anti-allergy Claritin tablets in the 10 mg strength, the FDA site www.fda.gov showed.
Mumbai, Aug 20: Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to market a generic version of Schering-Plough Corp's anti-allergy Claritin tablets in the 10 mg strength, the FDA site www.fda.gov showed.
Ranbaxy had earlier got a tentative nod for the 10 mg loratadine tablets in December 2001. The drug's patent expired last year and it is being sold in the over-the-counter market in the United States by several generic firms, besides the innovator Schering.
Claritin, once a blockbuster drug in Schering's stable, had U.S. sales of $944 million in the 12 months to June 2003. Bureau Report
Ranbaxy had earlier got a tentative nod for the 10 mg loratadine tablets in December 2001. The drug's patent expired last year and it is being sold in the over-the-counter market in the United States by several generic firms, besides the innovator Schering.
Claritin, once a blockbuster drug in Schering's stable, had U.S. sales of $944 million in the 12 months to June 2003. Bureau Report